Spyre Therapeutics (SYRE) is up 11.2%, or $4.25 to $42.06.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics: Advancing Inflammatory Disease Pipeline and 2026 Proof‑of‑Concept Catalysts Support Buy/High Risk Rating and $64 Target
- Spyre Therapeutics reports Q4 EPS (70c) vs. (81c) last year
- Spyre Therapeutics files automatic mixed securities shelf
- Spyre Therapeutics Accelerates SKYLINE Trial and Bolsters Leadership
- Spyre Therapeutics highlights 2026 priorities, appoints Cheveln as CCO